Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Silk bioprotein wound dressing for double‑incision mastectomy

Official title: The Utility of Silk Bioprotein as a Wound Dressing in Female-to-Male Double-Incision Mastectomy

Run by Indiana University · NCT06921148 · Data updated 2026-11-12

This project will test whether a silk bioprotein dressing reduces adhesive‑related skin injuries and other wound problems compared with Dermabond/Prineo in adults having double‑incision mastectomy for gender‑affirming surgery.

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment50 (estimated)
SponsorIndiana University
Academic / other
Drugs / interventionsradiation
Locations1 site (Indianapolis, Indiana)
StatusRecruiting
StartedSeptember 11, 2025
Main results expectedApril 30, 2028
Study endsJune 14, 2028
Registry record updatedNovember 4, 2026
Trial IDNCT06921148 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults (18+) scheduled for double‑incision bilateral mastectomy for female‑to‑male gender‑affirmation at Indiana University Health who do not meet exclusion criteria.

Probably not a fit

Patients with prior breast surgery or chest radiation, active conditions that impair wound healing, or known allergies to the dressings are unlikely to benefit or may be excluded.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults undergoing double‑incision bilateral mastectomy for female‑to‑male gender‑affirming surgery at Indiana University Health will receive either a silk bioprotein dressing (Sylk) or the standard Dermabond/Prineo dressing applied to their surgical incisions. Clinical staff will monitor participants during routine postoperative visits for adhesive‑related skin injuries, wound dehiscence, surgical‑site infection, and healing outcomes, and record any adverse reactions. Key exclusion criteria include prior breast surgery or radiation, a history of breast cancer, significant comorbidities that impair healing, or known allergies to either dressing. The trial compares the incidence and severity of skin reactions and wound complications between the two dressing groups to determine whether silk offers a safer alternative.

Why it matters

Potential benefit: If successful, the silk dressing could reduce adhesive‑related skin injuries and other wound complications, improving healing, comfort, and cosmetic outcomes after double‑incision mastectomy.

How similar studies have gone: Silk bioprotein has supportive preclinical and clinical data in tissue engineering, and a small number of prior clinical reports have shown safety and potential usefulness as a surgical dressing, but its use for this procedure is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients over the age of 18 undergoing double-incision bilateral mastectomy for female-to-male gender affirming surgery with the principal investigator.
* Physicians will be plastic surgeons in the IU Health system

Exclusion Criteria:

* Patients with a history of breast cancer.
* Patients with prior history of breast surgery.
* Patients with a prior history of radiation to the chest wall/breast.
* Patients with medical comorbidities that predispose to poor wound healing (diabetes, nutritional deficiency, smoking, inflammatory disease, chronic steroid use, immune deficiency, morbid obesity).
* Patients with a history of documented allergic reaction to Dermabond/Prineo or Silk Bioprotein dressing, or any of the constituents that make up these dressings.
* Significant acute or chronic medical, neurologic, or illness in the patient that, in the judgment of the Principal Investigator, could compromise subject safety, limit the ability to complete the study, and/or compromise the objectives of the study.
* Physicians not in the IU Health system will not be included.

Where it's running

  • Indiana University Health
    Indianapolis, Indiana, United States
    Recruiting

Study contacts

  • Principal investigator: Ivan Hadad, MD — Indiana University
  • Study coordinator: Ivan Hadad, MD
  • Email: ihadad@iu.edu
  • Phone: (317) 944-5000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.